History of gastrointestinal symptoms with other glucose-lowering agents is associated with gastrointestinal adverse events after imeglimin initiation: A retrospective real-world study

Aims/introduction

Imeglimin is an oral antidiabetic agent with a novel mechanism of action. Gastrointestinal (GI) adverse events (AEs) have been reported during imeglimin therapy. However, the factors associated with the occurrence of GI AEs have not been fully elucidated. This study aimed to investigate the incidence of GI AEs and the factors associated with their occurrence following imeglimin initiation.